Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19952748 | 0.84 | LOXL2 (0.68) | LOXL2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL20337951 | 0.84 | LOXL2 (0.70) | LOXL2SIGMAR1 | |
| SCHEMBL18362116 | 0.82 | LOXL2 (0.54) | LOXL2SIGMAR1 | |
| SCHEMBL18362014 | 0.80 | LOXL2 (0.57) | LOXL2 | |
| SCHEMBL20337855 | 0.80 | LOXL2 (0.58) | LOXL2SIGMAR1 | |
| SCHEMBL18362158 | 0.79 | LOXL2 (0.46) | LOXL2SIGMAR1 | |
| SCHEMBL18362119 | 0.78 | LOXL2 (0.53) | LOXL2SIGMAR1DRD2 | |
| SCHEMBL18362117 | 0.75 | SIGMAR1 (0.42) | SIGMAR1DRD2DRD3 | |
| SCHEMBL18362172 | 0.74 | LOXL2 (0.42) | LOXL2 | |
| SCHEMBL20337955 | 0.72 | ROCK1 (0.44) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| WO-2017003862-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LOXL2 1/4885SIGMAR1 3847/4885ACHE 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.